BioCentury on BioBusiness,
Table: BioDiscovery exits
Back to the parent article
Monday, March 4, 2013
Edmond de Rothschild Investment Partners closed
its first life sciences fund in 2000. Each successive fund has grown in
size, and the firm has returned money to investors every year since 2004. EdRIP
is looking to close BioDiscovery 4 this spring at €200 million ($267.6 million). Below are exits from its
life science-focused BioDiscovery funds. (A) Total raised by company from all
investors in indicated rounds; (B) Novexel S.A. is a BioDiscovery 2 and 3
portfolio company (C) U3 Pharma Inc. is a BioDiscovery 1 and 2 portfolio
company; Sources: BCIQ: BioCentury Online Intelligence; company press
3 fund ($244.1M)
against multi-drug resistant pathogens
2007 - $65M series B; 2009 - EdRIP, along with a syndicate of existing
investors, bought out the stake of another investor for an undisclosed sum
2010 - acquired by AstraZeneca plc (LSE:AZN; NYSE:AZN) for up to
$505M, including $75M in milestones
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]